Eris Lifesciences Limited Q2FY22 Revenues at INR 3,597 mn, up 9.0% YoY.
Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “Our consolidated revenue has grown by ~ 14% and Net Profit by 14.4% in the first half of this financial year. Our portfolio of power brands in cardio-metabolic and VMN continues to drive our growth. Nine out of our Top-15 mother brands are ranked among the Top-5 within their respective segments.
Our latest-generation Diabetes products Zomelis and Gluxit continue to enjoy #1 market ranks and robust growth. Of the 10 new product launches planned for FY22, we have launched 4 products in the first half of the year; we have more launches planned in H2 in the areas of Cardio-Metabolic, Wellness and Women’s Health. We have an exciting period of organic growth coming in the next 4 – 5 years, driven by multiple factors like consolidation of power brands franchise, new launch pipeline, expansion of physician coverage and therapeutic diversification. We continue to look for high-
return in-licensing and acquisition opportunities, in order to supplement our organic growth initiatives.”
Q2FY22 and H1FY22 – Financial Highlights
Revenue of Q2FY22 grew by 9.0% YoY to INR 3,597 mn and H1FY22 grew by 13.8% YoY to INR 7,089 mn; Branded Formulations revenue grew by 7.3% YoY to INR 3,283 mn in Q2FY22 and grew by 13.0% YoY to INR 6,426 mn in H1FY22
EBITDA grew by 12.1% YoY to INR 1,398 mn in Q2FY22 and grew by 16.4% YoY to INR 2,663 mn in H1FY22
PAT grew by 9.9% YoY to INR 1,184 mn in Q2FY22 and grew by 14.4% YoY to INR 2,251 mn in H1FY22
Q2FY22 – Business Highlights
Outperformed the market in Cardio-metabolic and CNS therapies which constitute 67% of our revenue
Won the prestigious award for IT digital transformation in an event conducted by Money Control and Network 18
Continued to support medical innovation with the “Metabolic Roadinar” – a first-of-its-kind initiative which will feature 18 well-known Endocrinologists and Diabetologists across the country in 9 episodes, discussing topics related to cardio-metabolic health. This format is expected to disrupt the CME landscape and give medical communication a new dimension.